Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 18/20 | 1.00 |
| ▸ | DHFR | P00374 | 2/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18624761 | 0.92 | DHODH (0.85) | DHODHDHFRNR4A2 | |
| SCHEMBL20673315 | 0.88 | DHODH (0.78) | DHODHDHFRNR4A2 | |
| SCHEMBL517489 | 0.87 | DHODH (1.00) | DHODHDHFRNR4A2 | |
| SCHEMBL4399438 | 0.82 | DHODH (0.74) | DHODHDHFR | |
| SCHEMBL299773 | 0.81 | DHODH (0.72) | DHODHDHFR | |
| SCHEMBL31326983 | 0.80 | DHODH (0.83) | DHODHDHFRNR4A2 | |
| SCHEMBL25839308 | 0.80 | DHODH (0.83) | DHODHDHFRNR4A2 | |
| Kio-100 SCHEMBL517019 | 0.79 | DHODH (1.00) | DHODHDHFR | |
| SCHEMBL14452168 | 0.79 | DHODH (0.85) | DHODHNR4A2 | |
| SCHEMBL31026697 | 0.78 | DHODH (0.77) | DHODHDHFRNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015154820-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GMBH (AT) | 2015-10-15 | — | — | WO | claimed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | claimed |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2023-09-14 | — | — | US | disclosed |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | KIORA PHARMACEUTICALS GMBH (AT) | 2023-08-22 | — | — | US | disclosed |
| EP-2427186-B1 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GES M B H (AT) | 2022-01-12 | — | — | EP | disclosed |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2019-01-24 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-20170071904-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | KIORA PHARMACEUTICALS GMBH (AT) | 2017-03-16 | — | — | US | disclosed |
| US-20170027905-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | Panoptes Hparma GmbH (AT) | 2017-02-02 | — | — | US | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2362771-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010128050-A2 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071904-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | DHODH 1/4885DHFR 38/4885NR4A2 3111/4885 |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | HLA-DRB1, IL2, SSB | DHODH 2305/4885DHFR 209/4885NR4A2 2709/4885 |
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | DHODH 1/4885DHFR 9/4885NR4A2 3748/4885 |
| US-11730716-B2 | Compounds for treating ophthalmic diseases and disorders | DHODH, ALDH1A2, QDPR | DHODH 1/4885DHFR 38/4885NR4A2 3111/4885 |
| US-20170027905-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, RPL35, NFKBIA | DHODH 2832/4885DHFR 3370/4885NR4A2 3102/4885 |
| US-20230285355-A1 | COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | DHODH, ALDH1A2, QDPR | DHODH 1/4885DHFR 38/4885NR4A2 3111/4885 |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, MIF, IL1B | DHODH 2796/4885DHFR 2698/4885NR4A2 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.